Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer

NCT01016639 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT01016639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01016639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
Lead sponsor
Lund University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2003
Completion date
July 31, 2009
Enrollment
106 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bile ductus cancer, colorectal cancer, gall bladder cancer, pancreas cancer, stomach cancer